ArticlemBio2025
Encephalomyocarditis virus protein 2B* interacts with 14-3-3 proteins through a phosphorylated C-terminal binding motif.
Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Encephalomyocarditis virus (EMCV) has been an important model RNA virus for decades. Although most of the EMCV proteins are obtained via proteolytic cleavage of a long polyprotein, 2B* is expressed from a short overlapping open reading frame via an unusual protein-stimulated temporally dependent ribosomal frameshifting mechanism. Mutant viruses that are unable to express 2B* have a small plaque phenotype due to delayed onset and inefficient progression of multiple lytic cell death pathways. However, the mechanism by which 2B* promotes these pathways has not yet been characterized. By tagging 2B* within the viral genome, we identified putative interaction partners of 2B* and showed that 2B* binds all seven members of the 14-3-3 protein family during virus infection. Binding is entirely dependent on a mode III motif containing a phosphoserine (RRNpSS) at the 2B* C terminus. This may impede other functions of the 14-3-3 proteins, including their role in promoting antiviral signaling. Ablating the 2B*:14-3-3 interaction had no effect upon plaque size, indicating that the function of this interaction is unrelated to the role of 2B* in promoting lytic cell death. This work expands our knowledge of the protein complement of this important model virus and the binding repertoire and specificity of host 14-3-3 proteins.IMPORTANCEEncephalomyocarditis virus (EMCV) infects a range of species, causing economically important reproductive disorders in pigs and encephalitis and myocarditis in rodents. Due to its wide host range, it is an important model pathogen for investigating virus-host interactions. EMCV expresses an accessory protein, 2B*, from an overlapping open reading frame via an unusual ribosomal frameshifting mechanism. Although the frameshifting mechanism has been established, the function of the 2B* protein had not been explored until recently. Here, we determined the host proteins to which 2B* binds and found that it specifically binds to all members of the 14-3-3 protein family, which, among other roles, contribute to the innate immune response to viral infection in mammalian cells. The interaction requires a specific stretch of amino acids at the end of 2B*. Binding to 2B* may reduce the opportunities for these 14-3-3 proteins to bind to host proteins and perform their usual roles; therefore, by interacting with the 14-3-3 proteins, 2B* may affect multiple host cell functions, including immune response activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.